Soluble complexes of curcumin
AssigneeNovobion Oy
InventorJaakko PARKKINEN
Life of this patent
Estimating the term…
Abstract
A composition comprising a water-soluble and stable complex formed by an alkyl ether derivative of gamma-cyclodextrin and curcumin and optionally comprising non-complexed cyclodextrin, the molar ratio of curcumin to cyclodextrin being between 1:1 and 1:6, and a method of manufacturing such a composition. The water-soluble and stable complex of curcumin is useful in therapy, e.g. for treatment of cancer, leukemia, myocardial infarction, stroke, sepsis, acute lung injury, acute liver failure, acute tubular necrosis, acute pancreatitis, radiation injury and other life-threatening conditions in a human or animal subject, as well as for preserving human or animal organs, tissues or cells at a hypothermic temperature.
Claims37
A composition comprising an aqueous phase and, dissolved in said aqueous phase, a water-soluble, stable complex formed by an alkyl or ether derivative of gamma-cyclodextrin and curcumin, and optionally comprising non-complexed cyclodextrin, the molar ratio of curcumin to cyclodextrin being between 1:1 and 1:6.
A method of producing a water-soluble complex of curcumin with an alkyl or ether derivative of gamma-cyclodextrin comprising:
- a) contacting curcumin with the gamma-cyclodextrin derivative in an aqueous phase at a pH of at least 11 to form a solution, and
- b) lowering the pH of the solution to below pH 8
- whereby a stable cyclodextrin complex of curcumin is formed in said aqueous phase.
A method for treating acute lung injury, lung fibrosis, asthma, chronic obstructive pulmonary disease and cystic fibrosis in a human or animal subject, comprising administering by inhalation an effective amount of a pharmaceutical composition containing an alkyl or ether derivative of gamma-cyclodextrin and curcumin.
A method for treating neurodegenerative and neuroinflammatory diseases, including multiple sclerosis, Parkinson's disease and Alzheimer's disease, brain tumors and stroke in a human or animal subject, comprising administering intranasally an effective amount of a pharmaceutical composition containing an alkyl or ether derivative of gamma-cyclodextrin and curcumin.
A method for treating bladder cancer in a human or animal subject, comprising administering intravesically an effective amount of a pharmaceutical composition containing an alkyl or ether derivative of gamma-cyclodextrin and curcumin.
A method of treating cancer, leukemia, myocardial infarction, stroke, sepsis, acute lung injury, acute liver failure, acute tubular necrosis, acute pancreatitis, graft versus host disease, graft rejection, radiation injury and other life-threatening conditions in a human or animal subject, comprising administering an effective amount of a pharmaceutical composition containing an alkyl or ether derivative of gamma-cyclodextrin and curcumin.
A method for treating or reducing mucositis in a human or animal subject, comprising administering an effective amount of a pharmaceutical composition containing an alkyl or ether derivative of gamma-cyclodextrin and curcumin.
A method of preventing and treating reperfusion injury during and after organ transplantations, thrombolytic therapy and other revascularization procedures, cardiovascular and angioplastic surgery, and shock in a human or animal subject, comprising administering intravascularly an effective amount of a pharmaceutical composition containing an alkyl or ether derivative of gamma-cyclodextrin and curcumin.
A method of preserving human or animal organs, tissues or cells at a hypothermic temperature comprising contacting the organs, tissues or cells with an effective amount of a medical composition containing an alkyl or ether derivative of gamma-cyclodextrin and curcumin.
A method of manufacturing an endotoxin-free cyclodextrin complex of curcumin comprising:
- a) contacting curcumin with the cyclodextrin in an aqueous phase at a pH of at least 11 to form a solution of curcumin and cyclodextrin,
- b) lowering the pH of said solution to below pH 8, and
- c) recovering the solution thus obtained containing an endotoxin-free cyclodextrin complex of curcumin.
Dependencies are inferred from the claim text.